5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity (Q37986694)

26 August 2017

title

5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity (English)

1 reference

26 August 2017

Bruce P Burnett

1

1 reference

26 August 2017

Robert M Levy

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

7 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

29

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

79-98

1 reference

An update on the role of leukotrienes in asthma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

A role for leukotriene antagonists in atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Role of leukotriene B4 receptors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Leukotriene signaling in atherosclerosis and ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

21 January 2018

Eicosanoids and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The role of leukotrienes in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Arachidonic acid as a bioactive molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Prostaglandin H synthase and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cyclooxygenase inhibition and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Relationship between cyclooxygenase-2 inhibition and thrombogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Nonsteroidal anti-inflammatory drugs: effects on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Harmful effects of NSAIDs among patients with hypertension and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

21 January 2018

5-lipoxygenase and FLAP

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Oxidants as stimulators of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Action of epoxyeicosatrienoic acids on cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Mechanisms of aspirin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Role of leukotriene C4 in mucosal damage caused by necrotizing agents and indomethacin in the rat stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Can the diagnosis of NSAID-induced or Hp-associated gastric ulceration be predicted from histology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Selective cyclooxygenase 2 inhibitors and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Differential leukotriene constrictor responses in human atherosclerotic coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Plasma polyunsaturated fatty acids and the decline of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Increased leukotriene B4 synthesis in immune injured rat glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

90-day oral toxicity study of UP446, a combination of defined extracts of Scutellaria baicalensis and Acacia catechu, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Arachidonic acid cascade and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

High levels of fat and (n-6) fatty acids in cancellous bone in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Neutrophil-derived leukotriene B4 is required for inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Leukotriene inhibition in small animal medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Leukotriene B4 potentiates colonic ulceration in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0100-7

10.1007/S12325-011-0100-7

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference